A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Completed · Phase 3

Conditions studied: Myelodysplastic Syndromes

In brief

The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).

Key facts

Study ID
NCT00050843
Run by
Celgene Corporation
People needed
220
Starts
2001-08-01
Expected to finish
2004-02-01
Last updated by the study team
2005-06-24

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.